HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: thx.2004.036046v1 60/9/713    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duffy, N Articles by Davies, L Search for Related Content PubMed PubMed Citation Articles by Duffy, N Articles by Davies, L Topic Collections Relevant Article

Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial

Aintree Chest Centre and University of Liverpool Department of Medicine, University Hospital Aintree, Liverpool, UK

Correspondence to:
Correspondence to:
Dr L Davies
Aintree Chest Centre, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK; lisa.davies{at}aht.nwest.nhs.uk

Background: Intravenous aminophylline is commonly used in the treatment of exacerbations of chronic obstructive pulmonary disease (COPD), despite limited evidence for its efficacy and known risks of toxicity. We hypothesised that adding intravenous aminophylline to conventional treatment would not produce clinically important changes in the speed of spirometric or symptomatic recovery or shorten hospital stay in patients with exacerbations of COPD.

Methods: Eighty patients admitted to hospital with non-acidotic exacerbations of COPD were recruited at admission to a randomised, double blind, placebo controlled study comparing intravenous aminophylline 0.5 mg/kg/hour after an appropriate loading dose with an equivalent volume of 0.9% saline. The primary outcome was the change in post-bronchodilator forced expiratory volume in 1 second (FEV₁) over the first 5 days of the admission. Secondary end points were changes in self-reported breathlessness, arterial blood gas tensions, forced vital capacity (FVC), and length of hospital stay.

Results: There was no difference in the post-bronchodilator FEV₁ over the first 5 days between the aminophylline and placebo groups. In the aminophylline group, 2 hours of treatment produced a small but significant rise in arterial pH (p = 0.001) and a fall in arterial carbon dioxide tension (p = 0.01) compared with placebo treatment. There were no differences in the severity of breathlessness, post-bronchodilator FVC, or length of hospital stay between the groups. Nausea was a more frequent side effect in the aminophylline group (46% v 22%; p<0.05), but palpitations and headache were noted equally in both groups.

Conclusions: Although intravenous aminophylline produced small improvements in acid-base balance, these did not influence the subsequent clinical course. No evidence was found for any clinically important additional effect of aminophylline treatment when used with high dose nebulised bronchodilators and oral corticosteroids. Given its known toxicity, we cannot therefore recommend the use of intravenous aminophylline in the treatment of non-acidotic COPD exacerbations.

Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity

Keywords: chronic obstructive pulmonary disease; exacerbations; aminophylline; theophylline

Relevant Article

Airwaves

Wisia Wedzicha
Thorax 2005 60: 709a. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				P. Albert and P. M. A. Calverley Drugs (including oxygen) in severe COPD Eur. Respir. J., May 1, 2008; 31(5): 1114 - 1124. [Abstract] [Full Text] [PDF]

				K. F. Rabe, S. Hurd, A. Anzueto, P. J. Barnes, S. A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. van Weel, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary Am. J. Respir. Crit. Care Med., September 15, 2007; 176(6): 532 - 555. [Abstract] [Full Text] [PDF]

				G. P Currie and J. A Wedzicha Acute exacerbations BMJ, July 8, 2006; 333(7558): 87 - 89. [Full Text] [PDF]

				B Chakrabarti and P M A Calverley Management of acute ventilatory failure. Postgrad. Med. J., July 1, 2006; 82(969): 438 - 445. [Abstract] [Full Text] [PDF]

				R Rodriguez-Roisin COPD exacerbations {middle dot} 5: Management. Thorax, June 1, 2006; 61(6): 535 - 544. [Abstract] [Full Text] [PDF]

				N. J. Stevenson, P. P. Walker, R. W. Costello, and P. M. A. Calverley Lung Mechanics and Dyspnea during Exacerbations of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1510 - 1516. [Abstract] [Full Text] [PDF]

				G I Town Aminophylline for COPD exacerbations? Not usually Thorax, September 1, 2005; 60(9): 709 - 709. [Full Text] [PDF]

eLetters: